France says hepatitis B vaccine benefits outweigh multiple sclerosis risks
This article was originally published in Scrip
Executive Summary
The pharmacovigilance committee of France's medicines regulator, Afssaps, has discounted the risk of a possible association between vaccination against hepatitis B and the risk of a first central demyelinating event in children that might indicate the early stages of multiple sclerosis. It concluded at its meeting on September 30th that the available evidence did not alter the benefit/risk profile of hepatitis B vaccination.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.